Q3 2025 Strides Pharma Science Ltd Earnings Call Transcript
Key Points
- Strides Pharma Science Ltd (BOM:532531) reported a strong quarter with a 13.3% year-on-year revenue growth, aligning with their guidance of 12% to 15%.
- The company achieved an EBITDA margin of 18.2% for Q3, with a year-to-date EBITDA of INR 585 crore, indicating robust operational performance.
- Strides successfully reduced its net debt to EBITDA ratio to under 2x, achieving this target one quarter ahead of schedule.
- The US business is on track to meet its revenue guidance of $275 million to $290 million, with five product approvals and four launches in the quarter.
- Strides received a strong ESG rating of 76/100 from S&P Global Corporate Sustainability assessment, outperforming industry peers in governance, social, and environmental metrics.
- The company faces challenges in the other regulated markets, with only a 1.8% year-on-year growth, and anticipates a breakout in performance only in the second half of the next fiscal year.
- Despite the strong quarter, the company acknowledges that the absolute percentage of EBITDA may not significantly increase in the near term.
- There are potential risks related to product approvals and regulatory compliance that could impact future performance.
- The anticipated growth in the other regulated markets has been delayed, with significant contributions expected only after 2 to 3 quarters.
- The company is still working on optimizing its working capital cycle, which is currently at 119 days, although it is already considered best in class.
Ladies and gentlemen, good day. And welcome to Stride Pharma Science Limited Q3 and 9MFY25 earnings conference call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. (Operator instructions) Please note that this conference is being recorded. I now hand the conference over to Mr. Abhishek. Thank you, and over to you, sir.
Hey, good afternoon, and thank you for joining us today for Stride's earnings call for the third quarter and nine months ended financial year 2025., Today, we have with us Arun, Founder and Executive Chairman; Badree, Managing Director and group CEO; and Vikesh Kumar, group CFO to share the highlights of the business and financials for the quarter.
I hope you've gone through our results release and the quarterly presentation that have been uploaded on our website as well as stock exchange website. The transcript for this call will be available in a week's time
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
